Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's lead product candidate includes VERVE-101. Verve Therapeutics is based in CAMBRIDGE, Mass.
| Revenue (Most Recent Fiscal Year) | $32.33M |
| Net Income (Most Recent Fiscal Year) | $-198.71M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 6.52 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.82 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -303.10% |
| Net Margin (Trailing 12 Months) | -303.64% |
| Return on Equity (Trailing 12 Months) | -35.81% |
| Return on Assets (Trailing 12 Months) | -27.57% |
| Current Ratio (Most Recent Fiscal Quarter) | 9.84 |
| Quick Ratio (Most Recent Fiscal Quarter) | 9.84 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $5.31 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.35 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.35 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.11 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 89.14M |
| Free Float | 71.40M |
| Market Capitalization | $388.66M |
| Average Volume (Last 20 Days) | 2.67M |
| Beta (Past 60 Months) | 1.82 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 19.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 97.11% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |